reason report
 guidanc rais gm shld pt
bottom line deliv rev/ep ahead consensu
first qtr bcr belt sale
out-performance favor fx prompt management increas
bd newco rev/ep guidanc result leav us
confid bdx/bcr newco abil deliv org cc top-
line growth mid-teen dd ep growth next year
bcr integr unfold management increas newco guidanc
cc revenue growth cc ep growth
captur street near midpoint revenue ep continu
posit regard ep step-up bcr transact
provid context volatil market may view
pt vs prior assum trade premium large-cap
get construct name like greater convict upsid
bcr synergi forecast order argu bigger multipl premium
large-cap med-tech diversifi vs current ascrib
turn price-to-earnings premium ep vs group
rev/ep help fx deliv sale
came ahead consensu
consensu org cc growth y/i cc beat us/
consensu y/i cc includ neg impact
us dispens chang fulli off-set impact
stronger flu season bd segment outperfom think
bd life scienc cc y/i out-performance aid
stronger flu season contribut growth bioscienc
cc diagnost cc bd medic cc deliv
upsid vs model includ neg impact
us dispens chang upsid segment
came pharmaceut system cc diabet cc
lesser extent medic deliveri solut cc bd
intervent cc deliv upsid driven strength
drug-coat balloon int biopsi product time capit order
temperatur management biz emerg market cc china
cc continu solid growth trend gm
consensu vs ebita mgn
basic line ultim higher-than-expect tax rate
off-set bigger expect fx tailwind result ep
beat consensu op margin ep includ
neg impact us dispens chang
medic suppli devic
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu bd onward new co inclus bcr oper deal close
bd onward new co inclus bcr oper deal close
pleas refer page import disclosur price chart analyst certif
midpoint ultim driven higher fx management
anticip revenu includ accret acquisit
bcr org cc vs cc includ rev
bcr current prior fiscal year increas
revenue estimate project org cc growth upper-end rang
cc guidanc includ bp headwind chang us
dispens busi model estim sale impact hurrican
maria puerto rico bcr busi exclud
item newco p-f org cc reg growth guidanc management
reiter bd medic bd intervent revenue guidanc base
strong perform ytd rais bd life scienc revenue growth outlook
cc vs cc prior dilut ep combin new co
expect rang vs prior
headwind tailwind off-set ep line
headwind includ neg impact due preanalyt
system pa cost associ addt clinic trial invest
improv qualiti system associ updat fda
observ neg impact due vyair
joint ventur divestitur neg impact resin
outlook increas net ultim allow
increment favor fx benefit flow get rais ep
management reaffirm gm guidanc op mgn
expans management continu expect
rang mgn improv y/i despit gm
shortfal vs street management highlight sever factor give
management confid gm rebound move includ
mix shift bcr higher average gm profil continu improv
initi base biz drive better throughout year
cost synergi -- conclus carefus synergi
last phase synergi focus cog improv initi
even benefit year bcr synergi procur
cog headwind us dispens chang goe
away favor price mix tailwind tap impact
full-year factor posit flow-through oper
mgn also expect see y/i improv
model y/i improv ebita mgn
synergi target re-affirmed management continu expect deliv
lsd ep accret hsd ep accret
well compani remain commit fulli realiz
synergi remaind ratabl
rate market perform pt vs pt prior follow fall
analyst day gain increas confid compani deliv organ top-lin
growth doubl digit cash ep growth next sever year growth
profil eye-pop respect believ continu
view investor reliabl msd top-lin dd bottom line grower med-tech bcr
transact close help acceler revenue growth level upper-end
msd rang rang well bcr anticip accret rev/cost synergi
target engend mid-teen ep growth year continu posit
regard ep step-up tap bcr think stock worth least
reflect ep step-up beyond
think compar larg diversifi med-tech peer group given
exposur across medic technolog life scienc acquisit bcr close
peer group includ trade ep
think trade least line group higher given in-lin higher
average top-lin ep growth prospect appli price-to-earnings prem vs peer group
multipl slightli lower pro forma ep forecast get vs
risk valuat includ accret estim bcr prove overli conserv
aggress fx volatil signific exposur emerg market revenue growth
volatil slower-than-anticip uptak compani diagnost
becton dickinson compani
dollar million except ep
margin sale
compani report factset consensu leerink partner llc estim
present prior-period reflect reclassif associ movement effet certain product
medic segment intervent segment
becton dickinson compani
dollar million except ep
total interest incom net
revenu
compani report leerink partner llc estim
becton dickinson compani
ex-fx adj respiratori
ex-fx adj respiratori sale
 ex-fx adj respiratori sale
bp op mgn expans
bp op mgn expans
bp op mgn expans
compani report leerink partner estim
becton dickinson compani
dollar million except per share data
product sold ex-amort ex-item
sell administr expens
research develop expens
total oper cost expens
fx neutral total oper cost expens
total interest incom net
alloc prefer secur
gaap ep avail common sharehold dilut
sell administr
research develop
total oper cost expens
sell administr
research develop
total oper cost expens
compani report leerink partner estim
sale report repres report revenue growth rate without exclus big step-up inclus bcr oper
pro-forma sale growth calcul base compar rev inclus bcr adjust fx impact
reflect report revenue growth bd stand-alone ex bcr
onward includ bcr oper report revenu
comment line item note guidanc commentari
becton dickinson compani
dollar million except per share data
note model reflect bcr combin sale
becton dickinson compani
dollar million except per share data
note model reflect bcr combin sale
becton dickinson compani
dollar million except per share data
note model reflect bcr combin sale
souc compani report leerink partner estim number may due round
